Insulin
The most powerful muscle-building hormone in your body — it drives nutrients (sugar, amino acids) directly into muscle cells. FDA-approved and essential for diabetes management. In bodybuilding, it's used for extreme muscle growth by forcing nutrients into muscles after workouts. However, it is the single most dangerous compound used in performance enhancement — a dosing error can cause seizures, brain damage, coma, or death within hours. The margin between an effective dose and a lethal dose is very small.
Dosage
Diabetes: individualized by physician. Off-label: EXTREMELY DANGEROUS
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Rapid-acting (Humalog/Novolog): 1 hour | Regular (Humulin R): 1.5 hours | Long-acting (Lantus): 24 hours
Half-Life Calculator →Administration
Subcutaneous injection. Timing varies by type (rapid, regular, long-acting).
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Nutrient Shuttling
Most potent anabolic hormone — drives glucose, amino acids, and nutrients into muscle cells.
Muscle Growth
Activates mTOR, suppresses protein degradation, and creates powerfully anabolic environment.
Blood Sugar Control
Essential for life in type 1 diabetes — the primary treatment for high blood sugar.
Mechanism of Action
Insulin is a 51-amino-acid peptide hormone composed of two disulfide-linked chains (A-chain: 21 amino acids, B-chain: 30 amino acids), produced by pancreatic beta cells in the islets of Langerhans. It is the body's master metabolic regulator and the most potent anabolic hormone, controlling glucose homeostasis, energy storage, and cell growth across virtually all tissues.
Insulin binds to the insulin receptor (IR), a transmembrane receptor tyrosine kinase that exists as a preformed dimer. Binding induces conformational changes that activate the intracellular tyrosine kinase domains, which autophosphorylate and then phosphorylate insulin receptor substrate (IRS) proteins. This initiates two major downstream cascades. The PI3K/Akt pathway drives the metabolic effects: Akt phosphorylation promotes GLUT4 glucose transporter translocation to the cell membrane (increasing glucose uptake 10-20 fold in muscle and adipose tissue), activates glycogen synthase (storing glucose as glycogen), activates mTORC1 (stimulating protein synthesis through S6K1 and 4E-BP1), and inhibits hormone-sensitive lipase (suppressing lipolysis and fat breakdown). The Ras/MAPK pathway mediates the growth and mitogenic effects: promoting cell proliferation and gene expression.
In bodybuilding contexts, insulin's extreme anabolic potency stems from its simultaneous activation of multiple anabolic pathways and suppression of catabolic ones. It drives amino acids and glucose into muscle cells while blocking protein degradation and fat mobilization, creating a powerfully anabolic environment. When combined with GH (which mobilizes fatty acids) and IGF-1 (which promotes satellite cell differentiation), insulin creates synergistic muscle growth. However, this same potency makes insulin acutely dangerous — severe hypoglycemia from dosing errors can cause seizures, brain damage, coma, and death within hours. The narrow therapeutic window and life-threatening consequences of overdose make insulin the highest-risk compound used in bodybuilding.
Regulatory Status
FDA approved. Prescription required for most formulations. Multiple manufacturers (Novo Nordisk, Eli Lilly, Sanofi). Over-the-counter in some US states for regular insulin.
Risks & Safety
Common
low blood sugar (sweating, shaking, confusion, hunger), lumps at injection sites, weight gain.
Serious
severe low blood sugar can cause seizures, unconsciousness, brain damage, coma, and death from dosing errors or missed meals.
Rare
severe allergic reactions, dangerously low potassium.
Compare Insulin With
Research Papers
35Published: February 11, 2026
AI Summary
GLP-1 drugs show promise in lab models of ALS but current clinical data do not support their use and raise safety concerns, especially around weight loss. More ALS-specific trials are needed before considering these drugs for this population.
Published: February 11, 2026
AI Summary
Weight-loss drugs that mimic GLP-1 mainly reduce appetite but do little to boost energy expenditure. Glucagon receptor agonists may help by increasing fat burning and metabolic rate, potentially improving long-term weight loss when combined with GLP-1 drugs.
Published: February 11, 2026
AI Summary
The Sim-Q questionnaire was developed to measure how simple or complex diabetes treatment feels to patients. The study evaluated whether the questionnaire is reliable and valid for use in type 2 diabetes.
Published: February 11, 2026
AI Summary
Obesity caused by hypothalamic damage is hard to treat with diet and exercise alone, but newer drugs targeting appetite and metabolism show promise. Combination therapies may eventually reduce the need for bariatric surgery in this population.
Published: February 1, 2026
AI Summary
Statins blocked insulin-driven breast cancer cell growth by suppressing a stress-related protein called NUPR1. Higher NUPR1 levels in patients predicted worse outcomes, supporting statins as a potential add-on treatment for breast cancers with strong insulin signaling.
Published: February 10, 2026
AI Summary
A frog-skin antimicrobial peptide with known anti-atherosclerosis effects may also slow type 2 diabetes in mice with artery disease. The abstract frames the rationale for testing whether treating atherosclerosis can lower diabetes risk.
Published: February 8, 2026
AI Summary
GLP-1 affects metabolism, inflammation, and aging through multiple pathways beyond blood sugar control. The review argues for better drug design and biomarkers to expand GLP-1-based treatments for age-related diseases, despite remaining safety questions.
Published: January 10, 2026
AI Summary
Nerve activity that calms the body declined as blood sugar control worsened in people with obesity and prediabetes. The link between nerve tone and inflammation was largely explained by belly fat, suggesting weight loss may help restore balance.
Published: January 9, 2026
AI Summary
Semaglutide improved acne, hidradenitis suppurativa, and oily skin over two years, with changes tied to better metabolic markers. The findings point to possible skin benefits from GLP-1 drugs, though more controlled trials are needed.
Published: January 25, 2026
AI Summary
Combining an IDO-1 inhibitor with icaritin may ease diabetes-related brain inflammation and cognitive problems. The abstract outlines the rationale for testing this combination in diabetes-associated cognitive dysfunction.
Published: March 4, 2026
AI Summary
Pesticide exposure may contribute to type 2 diabetes and brain inflammation partly by disrupting endocannabinoid signaling. The review explores whether targeting this system could help treat pesticide-related metabolic and neurological harm.
Published: February 10, 2026
AI Summary
Adjusting isoleucine and valine levels in feed influenced insulin function and relieved the negative effects of excess leucine in broiler chickens. The work clarifies how branched-chain amino acid balance affects metabolism in poultry.
Published: February 10, 2026
AI Summary
Insulin resistance drives metabolic disease, heart disease, and cancer, with the liver playing a central role. The review calls for managing insulin resistance as part of preventing and treating liver disease, including liver cancer.
Published: February 21, 2026
AI Summary
In obese youth without fatty liver disease, liver fat was still linked to higher FGF21, a stress-related hormone. The abstract highlights the need to understand metabolic risk even when liver fat is below the disease cutoff.
Published: February 24, 2026
AI Summary
Adding heparin to collagen scaffolds boosted muscle cell growth and differentiation by trapping more IGF-1. The results support heparin-modified scaffolds as a promising platform for engineering skeletal muscle tissue.
Published: February 15, 2026
AI Summary
Researchers developed a scale to measure how safely diabetes patients dispose of insulin pen needles. The work addresses an often-overlooked aspect of diabetes self-care and needle safety.
Published: February 6, 2026
AI Summary
The review covers how insulin, glucagon, amylin, and GLP-1 drugs are engineered for stability, longer action, and better delivery. These design principles could guide next-generation diabetes therapies and other protein-based drugs.
Published: February 8, 2026
AI Summary
Removing the protein lipocalin-2 reduced brain damage from seizures in diabetic mice by easing inflammation and iron-related stress. Targeting this pathway may help protect the brain when metabolism is impaired.
Published: December 8, 2025
AI Summary
The study examined the link between adiponectin and insulin resistance in obese adolescents and young adults. Understanding this relationship could inform strategies to improve metabolic health in this age group.
Published: January 31, 2026
AI Summary
A drug that blocks a specific protein-degradation enzyme improved blood sugar in obese mice by both sensitizing tissues to insulin and boosting insulin release. The dual mechanism could inform new diabetes treatments.
Published: January 22, 2025
AI Summary
Hormones like GLP-1 and leptin shape taste perception and appetite through a gut-brain-taste axis. The review explains how obesity and diabetes alter this system and may drive unhealthy eating patterns.
Published: January 20, 2026
AI Summary
Combining insulin-resistance markers with a heart failure marker improved prediction of bad outcomes after heart attack. The abstract frames the value of using these biomarkers together for risk stratification.
Published: February 8, 2026
AI Summary
A muscle-derived protein called SIRPα worsened diabetic kidney disease in mice by impairing insulin signaling and fat metabolism in the kidney. Blocking SIRPα protected the kidneys, suggesting it as a biomarker and drug target.
Published: February 19, 2026
AI Summary
Vesicles from mice lacking adiponectin carried lipids that promoted inflammation and impaired insulin action in recipient cells. Similar lipid changes in metabolic syndrome patients point to these vesicles as potential biomarkers and targets.
Published: February 8, 2026
AI Summary
A relaxin-like signal from ovary cells to neurons controlled when fruit flies ovulate and helped maintain egg quality. The findings support an ancient, conserved role for relaxin signaling in female reproduction.
Published: March 8, 2026
AI Summary
The article reviews how to evaluate and manage diabetes patients on insulin pumps or with pancreas transplants in the emergency setting. It covers common complications and diagnostic approaches for these specialized populations.
Published: March 8, 2026
AI Summary
The review covers diagnosis and treatment of diabetic ketoacidosis, including the rare euglycemic form, when to switch to subcutaneous insulin, and discharge planning. It offers practical guidance for emergency physicians managing these patients.
Published: February 5, 2026
AI Summary
Integrating clinical, imaging, and protein data revealed organ-specific and systemic drivers of fatty liver disease in people with and without type 2 diabetes. The approach could help identify targets for prevention and treatment.
Published: February 5, 2026
AI Summary
Tirzepatide outperforms GLP-1-only drugs for blood sugar and heart health, but its effects on the eyes are not well characterized. The abstract highlights the need to clarify ocular safety with this newer diabetes drug.
Published: February 8, 2026
AI Summary
Gut bacteria broke down a citrus polysaccharide into compounds that lowered blood sugar in diabetic mice by boosting GLP-1 and improving appetite regulation. The work supports developing this as a dietary supplement for type 2 diabetes.
Published: February 11, 2026
AI Summary
The study examined how long-acting insulin analogs affect the ability to measure natural insulin and C-peptide production in the body. Understanding this matters for distinguishing type 1 from type 2 diabetes when patients are already on insulin.
Published: February 11, 2026
AI Summary
Abstract too short to summarize.
Published: February 11, 2026
AI Summary
A protein called SerpinB2 helps fat tissue macrophages survive by supporting mitochondrial function. Obesity reduces SerpinB2, contributing to metabolic dysfunction, but restoring it or giving a glutathione precursor improved metabolic health in mice.
Published: February 12, 2026
AI Summary
Rolling out flash glucose monitoring for adults with type 2 diabetes on intensive insulin poses organizational challenges for health systems. The abstract introduces this topic without reporting outcomes.
Published: April 14, 2026
AI Summary
A sugar from a Chinese medicinal plant extended lifespan and reduced aging-related decline in worms and mice by dampening insulin/IGF-1 signaling. The findings support exploration of this compound for anti-aging applications.
Frequently Asked Questions
What is Insulin?
The most powerful muscle-building hormone in your body — it drives nutrients (sugar, amino acids) directly into muscle cells. FDA-approved and essential for diabetes management. In bodybuilding, it's used for extreme muscle growth by forcing nutrients into muscles after workouts. However, it is the single most dangerous compound used in performance enhancement — a dosing error can cause seizures, brain damage, coma, or death within hours. The margin between an effective dose and a lethal dose is very small.
What is Insulin used for?
The most powerful muscle-building hormone in your body — it drives nutrients (sugar, amino acids) directly into muscle cells. FDA-approved and essential for diabetes management. In bodybuilding, it's used for extreme muscle growth by forcing nutrients into muscles after workouts. However, it is the single most dangerous compound used in performance enhancement — a dosing error can cause seizures, brain damage, coma, or death within hours. The margin between an effective dose and a lethal dose is very small.
What is the dosage for Insulin?
Diabetes: individualized by physician based on blood glucose monitoring. Bodybuilding (extremely dangerous): 5-15 IU rapid-acting subcutaneous post-workout with mandatory high-carbohydrate and high-protein meal. Never to be used without blood glucose monitoring equipment immediately available.
What are the side effects of Insulin?
Common: low blood sugar (sweating, shaking, confusion, hunger), lumps at injection sites, weight gain. Serious: severe low blood sugar can cause seizures, unconsciousness, brain damage, coma, and death from dosing errors or missed meals. Rare: severe allergic reactions, dangerously low potassium.
How does Insulin work?
Insulin is a 51-amino-acid peptide hormone composed of two disulfide-linked chains (A-chain: 21 amino acids, B-chain: 30 amino acids), produced by pancreatic beta cells in the islets of Langerhans. It is the body's master metabolic regulator and the most potent anabolic hormone, controlling glucose homeostasis, energy storage, and cell growth across virtually all tissues. Insulin binds to the insulin receptor (IR), a transmembrane receptor tyrosine kinase that exists as a preformed dimer. Binding induces conformational changes that activate the intracellular tyrosine kinase domains, which autophosphorylate and then phosphorylate insulin receptor substrate (IRS) proteins. This initiates two major downstream cascades. The PI3K/Akt pathway drives the metabolic effects: Akt phosphorylation promotes GLUT4 glucose transporter translocation to the cell membrane (increasing glucose uptake 10-20 fold in muscle and adipose tissue), activates glycogen synthase (storing glucose as glycogen), activates mTORC1 (stimulating protein synthesis through S6K1 and 4E-BP1), and inhibits hormone-sensitive lipase (suppressing lipolysis and fat breakdown). The Ras/MAPK pathway mediates the growth and mitogenic effects: promoting cell proliferation and gene expression. In bodybuilding contexts, insulin's extreme anabolic potency stems from its simultaneous activation of multiple anabolic pathways and suppression of catabolic ones. It drives amino acids and glucose into muscle cells while blocking protein degradation and fat mobilization, creating a powerfully anabolic environment. When combined with GH (which mobilizes fatty acids) and IGF-1 (which promotes satellite cell differentiation), insulin creates synergistic muscle growth. However, this same potency makes insulin acutely dangerous — severe hypoglycemia from dosing errors can cause seizures, brain damage, coma, and death within hours. The narrow therapeutic window and life-threatening consequences of overdose make insulin the highest-risk compound used in bodybuilding.
How is Insulin administered?
Insulin is administered via subcutaneous injection. timing varies by type (rapid, regular, long-acting)..
What is the half-life of Insulin?
The half-life of Insulin is Rapid-acting (Humalog/Novolog): 1 hour | Regular (Humulin R): 1.5 hours | Long-acting (Lantus): 24 hours.
Is Insulin legal?
FDA approved. Prescription required for most formulations. Multiple manufacturers (Novo Nordisk, Eli Lilly, Sanofi). Over-the-counter in some US states for regular insulin.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.